GlassScriptPhysician profile
Alfredo M Lopez
NPI 1518958040
$3,905.62
in general payments reported to CMS, 2019-2025
30 companies · $419 in 2025
The $419 reported for 2025 was more than what 81% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $491 · 2020: $146 · 2021: $750 · 2022: $818 · 2023: $950 · 2024: $331 · 2025: $419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,227 · Travel and Lodging: $474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,226.66 |
| Travel and Lodging | $473.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $497.72 | 2019-2023 | Vns Therapy |
| Lilly USA, LLC | $380.44 | 2019-2023 | Mounjaro |
| Corcept Therapeutics | $362.87 | 2025 | Korlym |
| Eisai INC. | $326.15 | 2021-2024 | |
| Abbott Laboratories | $282.71 | 2021-2023 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $242.78 | 2019-2022 | |
| Boston Scientific Corporation | $230.78 | 2024 | Wavewriter Alpha Prime 16 |
| Janssen Pharmaceuticals, INC | $200.00 | 2020-2021 | |
| Novo Nordisk INC | $191.98 | 2020-2025 | Ozempic |
| Biohaven Pharmaceuticals, INC. | $187.64 | 2021 | |
| Amarin Pharma, INC. | $108.32 | 2019-2021 | |
| Nevro Corp. | $92.91 | 2021 | |
| Anx Robotica Corp | $86.91 | 2022 | |
| Pfizer INC. | $86.39 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.03 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $73.72 | 2022 | |
| Merck Sharp & Dohme LLC | $63.55 | 2019-2021 | |
| Seqirus USA INC | $59.01 | 2024-2025 | Flucelvax, Fluad |
| Vbi Vaccine (Delaware) INC. | $58.27 | 2022-2023 | Prehevbrio |
| Biogen, INC. | $56.35 | 2020-2023 | Spinraza |
| Redhill Biopharma INC. | $38.24 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $31.44 | 2019 | |
| Genzyme Corporation | $31.17 | 2019 | |
| Smith+Nephew, INC. | $31.09 | 2022 | |
| Glaxosmithkline, LLC. | $29.31 | 2022 | |
| Jazz Pharmaceuticals INC. | $22.88 | 2019 | |
| Hologic Sales and Service, LLC | $16.28 | 2022 | |
| Cranial Technologies, INC | $15.57 | 2023 | Doc Band |
| Shield Therapeutics INC | $13.01 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $11.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alfredo Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.